- Ensure all relevant members of staff have received the Field Safety Notice and the actions required are taken.
- For users who have the affected INFORM HPV III kit (lot Y19417):
- No replacement kits are currently available
- Clinical testing can continue, but only with same slide controls.
- Contact the manufacturer to discuss the best alternative or send testing to another laboratory
- Ensure all remaining listed products are not used for clinical testing, replacement kits are now available from the manufacturer.
- The use of appropriate same slide controls is highly recommended as it helps ensure the efficacy of all IHC and ISH assays carried out on every slide on automated instruments.
- Users who have not used same slide controls should consider a review of previous test results obtained using the affected lots.
- Report adverse events involving these devices through your local incident reporting system and/or your national incident reporting authority as appropriate: England, Scotland, Northern Ireland, Wales. You should also report directly to manufacturers if your local or national systems do not.
- Directors of pathology
- Laboratory Managers
- Consultant Histopathologists
- Lead Biomedical Scientists (Cytologists/Histologists)
- Purchasing managers
- General Surgeons
Deadlines for actions
Actions underway: 27 September 2018
Actions complete: 18 October 2018
Medical Device Safety Officers (in England)
Ask the manufacturer to add you to their distribution list for field safety notices (FSNs). This is to help with reconciliation.
If your organisation receives an FSN from a manufacturer, always act on it. Do not wait for a communication from MHRA.
In addition to the Field Safety Notice which details affected products, please refer to the spreadsheet which accompanies this MDA for additional unique device identification information.
||Expanded Affected Lots
||Previously Communicated Lots
|OptiView DAB IHC Detection Kit
||Y24225, Y25760, E00119
||Y19271, Y11625, Y15571
|ULTRAVIEW UNIVERSAL DAB DETECTION KIT
||Y09284, Y15384, Y18099, Y22153, Y11687, Y17984, Y19302, Y11716, Y18069
|iView DAB Detection Kit
|ultraView SISH Detection Kit
|OptiView Amplification Kit
||Y15435, Y19322, Y22447
|OptiView Amplification Kit (250 Test)
|ultraView SISH DNP Detection Kit
||Y10759, Y13938, Y17402, Y17403, Y21312
|ISH iVIEW Blue Plus Detection Kit
|ANTI-PAN KERATIN Primary Antibody, 25mL
|ultraView Universal Alkaline Phosphatase Red Detection Kit
||Y15071, Y18053, Y22469
|ISH Protease 3
||Y13927, Y18872, Y22569, Y25883
|CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody
||Y12992, Y18852, Y23051
|CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody
|VENTANA ISH iView Blue Detection Kit
|INFORM HPV III Family 16 Probe (B)
|VENTANA anti-Helicobacter Pylori (SP48) Rabbit Monoclonal Primary Antibody
|CINtec p16 Histology (250) CE
MHRA issued a Medical Device Alert in February 2018 alerting users to reagent dispenser issues which could lead to weak or absent staining of tissue samples.
The investigation identified the root cause was due to an inadequate application of oil in the manufacturing process. This has now been corrected.
These devices are used to detect markers in a range of pathological conditions including those associated with cancer (e.g. HPV, HER2, ER/PR, ALK and PD-L1).
As a consequence, there is a risk of false negative results (e.g. with all companion diagnostics such as HER2 tests) affecting clinical decisions for patients, due to commence treatment.
Roche Diagnostics Ltd
West Sussex RH15 9RY
Registration Number: 571546
Technical support helpline: 0808 100 1920
If you are responsible for cascading these alerts in your organisation, these are our suggested distribution lists.
Trusts (NHS boards in Scotland)
CAS and NICAS liaison officers for onward distribution to all relevant staff including:
- Biomedical science departments
- Clinical pathologists
- Clinical pathology directors
- Colposcopy departments
- General surgeons
- Gynaecology departments
- Medical directors
- Medical oncologists
- Medical oncology, directors of
- Purchasing managers
- Radiation & medical oncology departments
- Risk managers
- Supplies managers
Establishments registered with the Care Quality Commission (CQC) (England only)
- Hospitals in the independent sector
- Independent treatment centres
- Privatte medical practitioners
Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health’s Central Alerting System (CAS) by sending an email to: firstname.lastname@example.org and requesting this facility.
Send enquiries about this notice to MHRA, quoting reference number MDA/2018/029 or 2018/008/009/291/020
Emma Harris, MHRA
Tel: 020 3080 6685
Devices Clinical Team, MHRA
Tel: 020 3080 7274
Reporting adverse incidents in England
Through Yellow Card
Alerts in Northern Ireland are distributed via the NICAS system.
Enquiries and adverse incident reports in Northern Ireland should be addressed to:
Northern Ireland Adverse Incident Centre, CMO Group,
Department of Health, Social Services and Public Safety
Tel: 028 9052 3868
Northern Ireland Adverse Incident Centre (NIAIC)
Please report directly to NIAIC using the forms on our website.
Enquiries and adverse incident reports in Scotland should be addressed to:
Incident Reporting and Investigation Centre,
Health Facilities Scotland,
NHS National Services Scotland
Tel: 0131 275 7575
Reporting adverse incidents in Scotland
NHS Boards and Local Authorities in Scotland – report to Health Facilities Scotland.
Contractors such as private hospitals carrying out NHS work and private care homes that accept social work funded clients – report to Health Facilities Scotland.
Private facilities providing care to private clients report to the Care Inspectorate and MHRA.
Enquiries in Wales should be addressed to:
Healthcare Quality Division,
Tel: 02920 823 624 / 02920 825 510
Reporting adverse incidents in Wales
Report to MHRA through Yellow Card and follow specific advice for reporting in Wales in MDA/2004/054 (Wales).